Speakers from Touchstone Exploration, Shanta Gold, Savannah Resources and Kavango Resources feature in our Natural Resources webinar on May 25th. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Share News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 93.50
Bid: 93.00
Ask: 94.00
Change: -5.00 (-5.08%)
Spread: 1.00 (1.08%)
Open: 98.50
High: 98.50
Low: 93.50
Yest. Close: 98.50
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Ixico enters deal with NUY Langone Health for drug trial

Fri, 16th Oct 2020 16:23

(Sharecast News) - Data analytics company Ixico has entered into an agreement with NYU Langone Health to support a trial to determine if the immunosuppressant drug Sirolimus, approved by the FDA to prevent organ transplant rejection and for the treatment of a rare and progressive lung disease called lymphangioleiomyomatosis, is also able to slow the progression of disease in people with multiple system atrophy (MSA).

The AIM-traded firm said that, working with NYU Langone clinicians and researchers, the trial would help develop biomarkers for MSA from magnetic resonance imaging (MRI).

It described MSA as a condition of the central nervous system that causes gradual damage to nerve cells in the brain.

The project involves application of Ixico's existing MSA analysis solutions on retrospectively-collected MRI data from patients with MSA, dementia with Lewy bodies, Parkinson's disease, and progressive supranuclear palsy, as well as the joint development of a novel solution to analyse susceptibility weighted imaging (SWI).

"This collaboration will help to accelerate the quest for new treatments for multiple system atrophy by bringing together some of the leading researchers in the field from both academia and industry with the specific goal of developing new tools to better understand and characterise this debilitating disease," said Ixico's senior vice-president for science and innovation, Dr Robin Wolz.

At 1342 BST, shares in Ixico were up 1.06% at 89.94p.

More News

Ixico H1 revenues grow despite Covid-19 impacts on clinical development sector

(Sharecast News) - Clinical research firm Ixico said on Monday that revenues were expected to have improved in the six months ended 31 March, despite the impacts of the Covid-19 pandemic on the clinical development sector.

26 Apr 21 09:06

Ixico strikes collaboration deal with Microsoft

(Sharecast News) - Data analytics company Ixico said on Monday that it had struck a collaboration agreement with tech giant Microsoft to develop its artificial intelligence analytics platform for the global pharmaceutical industry.

15 Mar 21 10:13

Ixico selected for Alzheimer's clinical trial

(Sharecast News) - Neuroscience artificial intelligence (AI) analytics company Ixico has been selected by a current mid-sized biopharmaceutical client to support a phase 2 Alzheimer's disease clinical trial, it announced on Wednesday.

10 Mar 21 14:30

Ixico awarded ?3.4m contract by existing client

(Sharecast News) - Artificial intelligence (AI) data analytics company Ixico has been awarded a £3.4m contract to run over 4.5 years by an existing client, it announced on Thursday, for a spinocerebellar ataxia type-3 (SCA3) trial.

24 Dec 20 12:20

Ixico to provide neuroimaging solutions to unnamed global pharmaceutical group

(Sharecast News) - Data analytics firm Ixico has secured a contract for neuroimaging solutions with a "large global pharmaceutical company".

8 Dec 20 09:26

Ixico executes contract for Huntington's disease clinical trial

(Sharecast News) - Neuroscience data analytics company Ixico has executed a contract to provide neuroimaging services that would support a phase 1b and 2 clinical trial for Huntington's disease, it announced on Friday.

27 Nov 20 12:09

Ixico wins new contracts in Alzheimer's clinical trials

(Sharecast News) - Neuroscience data analytics company Ixico has secured new contracts in Alzheimer's disease (AD) clinical trials, it announced on Tuesday.

3 Nov 20 10:43

Ixico secures two Huntington's disease clinical trial contracts

(Sharecast News) - Neuroscience data analytics company Ixico has secured new contracts in Huntington's disease clinical trials.

22 Oct 20 15:00

Ixico FY revenues grow by more than a quarter

(Sharecast News) - AI data analytics company Ixico said on Monday that full-year revenues were up year-on-year as its data analytics service strategy continued to drive growth.

19 Oct 20 09:38

Ixico enters deal with NUY Langone Health for drug trial

(Sharecast News) - Data analytics company Ixico has entered into an agreement with NYU Langone Health to support a trial to determine if the immunosuppressant drug Sirolimus, approved by the FDA to prevent organ transplant rejection and for the treatment of a rare and progressive lung disease called lymphangioleiomyomatosis, is also able to slow the progression of disease in people with multiple system atrophy (MSA).

16 Oct 20 16:23

Ixico joins Friedreich's Ataxia research consortium

(Sharecast News) - Data analytics company Ixico has entered into a five-year collaboration with the Friedreich's Ataxia Research Alliance (FARA), it announced on Thursday, which it described as a non-profit organization dedicated to the pursuit of scientific research leading to treatments and a cure for Friedreich's Ataxia (FA).

24 Sep 20 16:30

Ixico joins Friedreich's Ataxia research consortium

(Sharecast News) - Data analytics company Ixico has entered into a five-year collaboration with the Friedreich's Ataxia Research Alliance (FARA), it announced on Thursday, which it described as a non-profit organization dedicated to the pursuit of scientific research leading to treatments and a cure for Friedreich's Ataxia (FA).

24 Sep 20 16:30

Ixico selected to support Alzheimer's trial

(Sharecast News) - Data analytics company Ixico has been selected by the Global Alzheimer's Platform Foundation (GAP) to support its planned 'Bio-Hermes' trial.

21 Sep 20 13:35

Ixico FY revenues, underlying earnings ahead of forecasts

(Sharecast News) - Data analytics company Ixico said on Monday that it had recorded "stronger-than-anticipated" second-half revenues and underlying earnings despite Covid-19.

24 Aug 20 09:18

Ixico sees only 'modest' impact on trading from Covid-19

(Sharecast News) - Data analytics company Ixico said on Wednesday that Covid-19 had only had a "modest" impact on trading and stated it expects to maintain double-digit revenue growth in 2021.

24 Jun 20 09:41

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.